Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2010 3
2011 2
2012 13
2013 12
2014 21
2015 45
2016 57
2017 62
2018 84
2019 114
2020 141
2021 124
2022 112
2023 94
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

805 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Armstrong AW, et al. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. J Am Acad Dermatol. 2023. PMID: 35820547 Free article. Clinical Trial.
BACKGROUND: Effective, well-tolerated oral psoriasis treatments are needed. OBJECTIVE: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe …
BACKGROUND: Effective, well-tolerated oral psoriasis treatments are needed. OBJECTIVE: To compare the efficacy and safety of deucrava …
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
METHODS: POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254). ...CONCLUSION: Deucravacitinib demons …
METHODS: POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucrava …
Apremilast for psoriasis treatment.
Carrascosa JM, Del-Alcazar E. Carrascosa JM, et al. G Ital Dermatol Venereol. 2020 Aug;155(4):421-433. doi: 10.23736/S0392-0488.20.06684-5. Epub 2020 Jun 15. G Ital Dermatol Venereol. 2020. PMID: 32545946 Free article. Review.
Efficacy of apremilast in moderate-to-severe psoriasis has been demonstrated in the pivotal trials, with a 30% PASI-75 response rate at week 16, an efficacy that was maintained through week 52. Apremilast also achieved significant responses in disease involvi …
Efficacy of apremilast in moderate-to-severe psoriasis has been demonstrated in the pivotal trials, with a 30% PASI-75 respons …
The Use of Apremilast in Psoriasis: A Delphi Study.
Carrascosa JM, Belinchón I, Rivera R, Ara M, Bustinduy M, Herranz P. Carrascosa JM, et al. Actas Dermosifiliogr (Engl Ed). 2020 Mar;111(2):115-134. doi: 10.1016/j.ad.2019.07.005. Epub 2019 Dec 19. Actas Dermosifiliogr (Engl Ed). 2020. PMID: 31864537 Review. English, Spanish.
The scenario in which the use of apremilast was considered to have the greatest possibility of success was in patients with stable moderate psoriasis. ...Consensus was reached that apremilast is an appropriate treatment for psoriasis in difficult locat …
The scenario in which the use of apremilast was considered to have the greatest possibility of success was in patients with stable mo …
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW, Read C. Armstrong AW, et al. JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006. JAMA. 2020. PMID: 32427307 Review.
OBSERVATIONS: Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psoriasis have been in its pathogenesis, genetics, comorbidities, and biologic treatments. ...Oral treatments include traditional agents such …
OBSERVATIONS: Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psori …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Free article. Clinical Trial.
OBJECTIVE: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis. ...CONCLUSIONS: Apremilast was effective in moderate to severe plaque psoriasis....
OBJECTIVE: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis. ...C …
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
OBJECTIVES: This study compared the efficacy and safety of risankizumab and apremilast in adults with moderate plaque psoriasis eligible for systemic therapy. ...Diarrhoea, nausea and headache were most frequent among apremilast-treated patients. CONCLUSIONS: …
OBJECTIVES: This study compared the efficacy and safety of risankizumab and apremilast in adults with moderate plaque psoriasis …
Psoriasis: a brief overview.
Raharja A, Mahil SK, Barker JN. Raharja A, et al. Clin Med (Lond). 2021 May;21(3):170-173. doi: 10.7861/clinmed.2021-0257. Clin Med (Lond). 2021. PMID: 34001566 Free PMC article.
Psoriasis is a clinically heterogeneous lifelong skin disease that presents in multiple forms such as plaque, flexural, guttate, pustular or erythrodermic. An estimated 60 million people have psoriasis worldwide, with 1.52% of the general population affected in the …
Psoriasis is a clinically heterogeneous lifelong skin disease that presents in multiple forms such as plaque, flexural, guttate, pust …
Apremilast for the treatment of psoriasis.
Chimenti MS, Gramiccia T, Saraceno R, Bianchi L, Garofalo V, Buonomo O, Perricone R, Chimenti S, Chiricozzi A. Chimenti MS, et al. Expert Opin Pharmacother. 2015;16(13):2083-94. doi: 10.1517/14656566.2015.1076794. Epub 2015 Aug 4. Expert Opin Pharmacother. 2015. PMID: 26243735 Review.
Apremilast , Otezla, is an oral small molecule recently approved for the treatment of patients with moderate-to-severe plaque psoriasis. ...Several drug peculiarities, such as the low frequency of adverse events and the oral route of administration, make apremila …
Apremilast , Otezla, is an oral small molecule recently approved for the treatment of patients with moderate-to-severe plaque psor …
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.
Jiang Y, Chen Y, Yu Q, Shi Y. Jiang Y, et al. BioDrugs. 2023 Jan;37(1):35-55. doi: 10.1007/s40259-022-00569-z. Epub 2023 Jan 2. BioDrugs. 2023. PMID: 36592323 Free PMC article. Review.
Small-molecule inhibitors, such as apremilast and deucravacitinib, are also approved for the treatment of psoriasis. ...Apremilast may induce weight loss as an adverse effect, presenting also with some beneficial metabolic actions. ...
Small-molecule inhibitors, such as apremilast and deucravacitinib, are also approved for the treatment of psoriasis. ...Apr …
805 results

Searches related to "psoriasis apremilast"